Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleDrug Discovery and Translational Medicine

Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor

Licheng Shi, Sonya G. Lehto, Dawn X. D. Zhu, Hong Sun, Jianhua Zhang, Brian P. Smith, David C. Immke, Kenneth D. Wild and Cen Xu
Journal of Pharmacology and Experimental Therapeutics January 2016, 356 (1) 223-231; DOI: https://doi.org/10.1124/jpet.115.227793
Licheng Shi
Department of Neuroscience (L.S., S.G.L., D.X.D.Z., H.S., J.Z., D.C.I., K.D.W., C.X.), Department of Global Biostatistical Science (B.P.S.), Amgen Inc., Thousand Oaks, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonya G. Lehto
Department of Neuroscience (L.S., S.G.L., D.X.D.Z., H.S., J.Z., D.C.I., K.D.W., C.X.), Department of Global Biostatistical Science (B.P.S.), Amgen Inc., Thousand Oaks, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dawn X. D. Zhu
Department of Neuroscience (L.S., S.G.L., D.X.D.Z., H.S., J.Z., D.C.I., K.D.W., C.X.), Department of Global Biostatistical Science (B.P.S.), Amgen Inc., Thousand Oaks, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Sun
Department of Neuroscience (L.S., S.G.L., D.X.D.Z., H.S., J.Z., D.C.I., K.D.W., C.X.), Department of Global Biostatistical Science (B.P.S.), Amgen Inc., Thousand Oaks, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianhua Zhang
Department of Neuroscience (L.S., S.G.L., D.X.D.Z., H.S., J.Z., D.C.I., K.D.W., C.X.), Department of Global Biostatistical Science (B.P.S.), Amgen Inc., Thousand Oaks, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian P. Smith
Department of Neuroscience (L.S., S.G.L., D.X.D.Z., H.S., J.Z., D.C.I., K.D.W., C.X.), Department of Global Biostatistical Science (B.P.S.), Amgen Inc., Thousand Oaks, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David C. Immke
Department of Neuroscience (L.S., S.G.L., D.X.D.Z., H.S., J.Z., D.C.I., K.D.W., C.X.), Department of Global Biostatistical Science (B.P.S.), Amgen Inc., Thousand Oaks, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth D. Wild
Department of Neuroscience (L.S., S.G.L., D.X.D.Z., H.S., J.Z., D.C.I., K.D.W., C.X.), Department of Global Biostatistical Science (B.P.S.), Amgen Inc., Thousand Oaks, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cen Xu
Department of Neuroscience (L.S., S.G.L., D.X.D.Z., H.S., J.Z., D.C.I., K.D.W., C.X.), Department of Global Biostatistical Science (B.P.S.), Amgen Inc., Thousand Oaks, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Therapeutic agents that block the calcitonin gene–related peptide (CGRP) signaling pathway are a highly anticipated and promising new drug class for migraine therapy, especially after reports that small-molecule CGRP-receptor antagonists are efficacious for both acute migraine treatment and migraine prevention. Using XenoMouse technology, we successfully generated AMG 334, a fully human monoclonal antibody against the CGRP receptor. Here we show that AMG 334 competes with [125I]-CGRP binding to the human CGRP receptor, with a Ki of 0.02 nM. AMG 334 fully inhibited CGRP-stimulated cAMP production with an IC50 of 2.3 nM in cell-based functional assays (human CGRP receptor) and was 5000-fold more selective for the CGRP receptor than other human calcitonin family receptors, including adrenomedullin, calcitonin, and amylin receptors. The potency of AMG 334 at the cynomolgus monkey (cyno) CGRP receptor was similar to that at the human receptor, with an IC50 of 5.7 nM, but its potency at dog, rabbit, and rat receptors was significantly reduced (>5000-fold). Therefore, in vivo target coverage of AMG 334 was assessed in cynos using the capsaicin-induced increase in dermal blood flow model. AMG 334 dose-dependently prevented capsaicin-induced increases in dermal blood flow on days 2 and 4 postdosing. These results indicate AMG 334 is a potent, selective, full antagonist of the CGRP receptor and show in vivo dose-dependent target coverage in cynos. AMG 334 is currently in clinical development for the prevention of migraine.

Footnotes

    • Received July 16, 2015.
    • Accepted November 10, 2015.
  • ↵1 Both L.S. and S.G.L. contributed equally to this work.

  • This work was funded by Amgen, Inc.

  • This work was previously presented as an oral presentation at the 56th Annual Scientific Meeting of the American Headache Society (June 26 - June 29, 2014; Los Angeles, CA) and published as Xu C, Shi L, Rao S, King C, Sun H, Zhu D, Lehto S, Wild K, and Immke D (2014) AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor. J Headache Pain 15(Suppl 1):G43.

  • dx.doi.org/10.1124/jpet.115.227793.

  • Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 356 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 356, Issue 1
1 Jan 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleDrug Discovery and Translational Medicine

Pharmacologic Characterization of AMG 334

Licheng Shi, Sonya G. Lehto, Dawn X. D. Zhu, Hong Sun, Jianhua Zhang, Brian P. Smith, David C. Immke, Kenneth D. Wild and Cen Xu
Journal of Pharmacology and Experimental Therapeutics January 1, 2016, 356 (1) 223-231; DOI: https://doi.org/10.1124/jpet.115.227793

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleDrug Discovery and Translational Medicine

Pharmacologic Characterization of AMG 334

Licheng Shi, Sonya G. Lehto, Dawn X. D. Zhu, Hong Sun, Jianhua Zhang, Brian P. Smith, David C. Immke, Kenneth D. Wild and Cen Xu
Journal of Pharmacology and Experimental Therapeutics January 1, 2016, 356 (1) 223-231; DOI: https://doi.org/10.1124/jpet.115.227793
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • SGS742 and Treatment of GHB Overdoses
  • Fate determination role of erythropoietin and romiplostim
  • Pharmacology of Antifentanyl mAb with Naloxone in Rats
Show more Drug Discovery and Translational Medicine

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics